CUMULATIVE ACTIVITY AS OF THE END OF DECEMBER 2017
in thousands of euros
2016
2017
Variation at current exchange rates
Variation at constant exchange rates
France
370,870
378,487
+2.1%
+2.1%
Europe (excluding France)
163,849
155,151
-5.3%
-7.3%
North America
64,916
68,572
+5.6%
+7.4%
Other countries
14,854
15,330
+3.2%
+1.5%
Group total
614,489
617,540
+0.5%
+0.1%
in thousands of euros
2016
2017
Variation at current exchange rates
Variation at constant exchange rates
Non-proprietary Homeopathic Medicines
313,365
310,594
-0.9%
-0.8%
OTC Specialties
299,672
305,552
+2.0%
+1.1%
Other
1 452
1 394
-4.0%
-4.1%
Group total
614,489
617,540
+0.5%
+0.1%
QUARTERLY ACTIVITY IN 2017 (variation at current exchange rate)
in thousands of euros
1st quarter
2nd quarter
3rd quarter
4th quarter
2016
2017
Var. 17/16
2016
2017
Var. 17/16
2016
2017
Var. 17/16
2016
2017
Var. 17/16
France
90,494
97,134
+7.3%
80,469
79,328
-1.4%
98,840
101,423
+2.6%
101,067
100,602
-0.5%
Europe (excluding France)
43,685
40,418
-7.5%
31,572
27,421
-13.1%
41,273
42,319
+2.5%
47,319
44,993
-4.9%
North America
16,064
18,179
+13.2%
14,113
14,465
+2.5%
16,020
16,055
+0.2%
18,719
19,873
+6.2%
Other countries
3,846
4,532
+17.8%
4,061
3,191
-21.4%
3,280
4,126
+25.8%
3,667
3,481
-5.1%
Group total
154,089
160,263
+4.0%
130,215
124,405
-4.5%
159,413
163,923
+2.8%
170,772
168,949
-1.1%
in thousands of euros
1st quarter
2nd quarter
3rd quarter
4th quarter
2016
2017
Var. 17/16
2016
2017
Var. 17/16
2016
2017
Var. 17/16
2016
2017
Var. 17/16
Non-proprietary Homeopathic Medicines
80,147
81,016
+1.1%
76,001
74,567
-1.9%
73,913
74,350
+0.6%
83,304
80,661
-3.2%
OTC Specialties
73,743
78,968
+7.1%
53,719
49,391
-8.1%
85,319
89,342
+4.7%
86,891
87,851
+1.1%
Other
199
279
+40.2%
495
447
-9.7%
181
231
+27.6%
577
437
-24.3%
Group total
154,089
160,263
+4.0%
130,215
124,405
-4.5%
159,413
163,923
+2.8%
170,772
168,949
-1.1%
HIGHLIGHTS OF THE FOURTH QUARTER
Sales revenue of the fourth quarter 2017 decreased by 1.1% (-0.4% at constant exchange rates). Sales of non-proprietary homeopathic medicines were down by 3.2%. Sales of OTC specialties were up by 1.1%, with a decrease of 13.3% in Russia and an increase of 2.3% in France and 13.2% in the USA.
Annual sales revenue amounted €617,540 thousand and was stable in comparison to 2016 (+0.5% at current exchange rates and +0.1% at constant exchange rates).
The operating income of 2017 should be lower than in 2016.
Our company carries on the development of homeopathy in the world with the same determination.
Our next update: March 14, 2018, after the close of the stock market, publication of 2017 results.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail: boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at: www.boironfinance.com
Regulated information
News releases under ongoing reporting obligations:
- Information on annual revenues
Full and original press release in PDF:
https://www.actusnews.com/documents_communiques/ACTUS-0-51750-boi-250118-ca-17-gb.pdf
Receive by email the next press releases of the company by registering on
www.actusnews.com, it′s free
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (52.4%), Europe (22.5%), North America (22.6%) and other (2.5%).
BOIRON 
